Equities

Renalytix PLC

RENX:LSE

Renalytix PLC

Health CareHealth Care Providers
  • Price (GBX)17.00
  • Today's Change-0.50 / -2.86%
  • Shares traded81.00k
  • 1 Year change-79.39%
  • Beta1.7580
Data delayed at least 20 minutes, as of Jun 24 2024 09:43 BST.
More ▼

Profile data is unavailable for this security.

About the company

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

  • Revenue in GBP (TTM)2.69m
  • Net income in GBP-36.55m
  • Incorporated2018
  • Employees80.00
  • Location
    Renalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
  • Phone+44 29 2071 0570
  • Websitehttps://renalytix.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Cambridge Cognition Holdings PLC13.52m-3.51m17.10m119.0017.10m119.00
Pebble Beach Systems Group PLC12.37m1.53m17.13m95.0017.13m95.00
Ingenta PLC10.83m2.30m17.15m71.0017.15m71.00
Crimson Tide plc6.16m-305.00k17.42m48.0017.42m48.00
Insig Ai PLC2.02m-17.56m18.84m112.0018.84m112.00
Narf Industries PLC3.27m-14.56m19.54m0.0019.54m0.00
essensys PLC24.08m-10.73m19.73m171.0019.73m171.00
Finseta PLC9.65m2.13m20.38m34.0020.38m34.00
Tinybuild Inc35.32m-49.46m24.71m400.0024.71m400.00
Checkit PLC12.00m-4.50m24.84m158.0024.84m158.00
Renalytix PLC2.69m-36.55m27.04m80.0027.04m80.00
Fadel Partners Inc11.46m-1.22m27.94m116.0027.94m116.00
Altitude Group PLC22.86m511.00k30.07m78.0030.07m78.00
GetBusy PLC21.11m-227.00k35.65m146.0035.65m146.00
Tpximpact Holdings PLC77.22m-24.07m38.71m735.0038.71m735.00
Data as of Jun 24 2024. Currency figures normalised to Renalytix PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.00%Per cent of shares held by top holders
HolderShares% Held
Polar Capital LLPas of 30 Apr 202413.87m8.98%
Harwood Capital LLPas of 15 Mar 202410.78m6.98%
Jefferson River Capital LLCas of 10 Apr 20248.53m5.53%
Pentwater Capital Management LPas of 24 Apr 20245.79m3.75%
Lombard Odier Asset Management (Europe) Ltd.as of 24 Apr 20244.00m2.59%
Susquehanna Investment Group LLCas of 18 Jun 20242.30m1.49%
Gilder, Gagnon, Howe & Co. LLCas of 12 Mar 20241.52m0.99%
Unicorn Asset Management Ltd.as of 04 Mar 20241.18m0.76%
Chelverton Asset Management Ltd.as of 30 Jun 20231.05m0.68%
Canaccord Genuity Wealth Ltd.as of 30 Apr 2024389.46k0.25%
More ▼
Data from 31 Mar 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.